Drug Trial Radar · NCT07154264
A Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10)
Last checked: Nov 19, 2026Latest source record: Jun 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
66
Planned (sponsor's estimate)
Start
Sep 22, 2025
Primary completion
Dec 2029
Study completion Jan 2030
Sponsor
- Lead sponsor
- Dizal PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Sep 4, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase 2 study to investigate the efficacy and safety of DZD8586 in combination in participants with CLL/SLL. This study consists of two parts: Part A is the safety lead-in phase, and Part B is the dose expansion phase.
Conditions
- Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Interventions
DZD8586Drug
DZD8586 will be taken orally once daily on days 1-28 of each cycle.
VenetoclaxDrug
Venetoclax will be taken orally once daily on days 1-28 starting from cycle 4 day 1.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: Incidence of Adverse EventsTime frame: 30 days after the last dose
- Part B: 2-year progression free survival (PFS) rate assessed by investigatorTime frame: Approximately 5 years
Locations
15 sites in 1 country. Site status is shown where the registry gives one.
Anhui Provincial Cancer Hospital
Hefei, Anhui, China · Recruiting
Peking University Third Hospital
Beijing, Beijing Municipality, China · Recruiting
Zhujiang Hospital of Southern Medical University
Guangzhou, Guangdong, China · Recruiting
Nanfang Hospital, Southern Medical University
Guangzhou, Guangdong, China · Recruiting
Henan Cancer Hospital
Zhengzhou, Henan, China · Recruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China · Recruiting
Yichang Central People's Hospital
Yichang, Hubei, China · Recruiting
Hunan Cancer Hospital
Changsha, Hunan, China · Recruiting
The First People's Hospital of Changzhou
Changzhou, Jiangsu, China · Recruiting
Affiliated Hospital of Nantong University
Nantong, Jiangsu, China · Recruiting
The First Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China · Recruiting
The First Bethune Hospital of Jilin University
Changchun, Jilin, China · Recruiting
Shengjing Hospital of China Medical University
Shenyang, Liaoning, China · Not yet recruiting
West China Hospital of Sichuan University
Chengdu, Sichuan, China · Recruiting
The First Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.